Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.

Autor: Wehmeyer MH; I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany., Jordan S; I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany., Lüth S; I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany., Hartl J; I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany., Stoehr A; Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany., Eißing C; I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany., Lohse AW; I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg Site, Germany., Petersen J; Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany., Buggisch P; Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany., Schulze Zur Wiesch J; I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg Site, Germany. Electronic address: j.schulze-zur-wiesch@uke.de.
Jazyk: angličtina
Zdroj: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2015 Sep; Vol. 47 (9), pp. 811-4. Date of Electronic Publication: 2015 May 24.
DOI: 10.1016/j.dld.2015.05.018
Abstrakt: Background: There are only limited data on sofosbuvir-based treatment regimens in hepatitis C virus (HCV) genotype 4-infected patients.
Aims: To evaluate safety and efficacy of sofosbuvir-based triple-therapy in HCV genotype 4 infection.
Methods: All HCV genotype 4-infected patients who started sofosbuvir-based triple-therapy at our two centres between January and June 2014 were prospectively included (N=24) and compared to genotype 4 patients treated with peginterferon/ribavirin between January 2001 and December 2012 (N=63).
Results: The demographics in the sofosbuvir group and the controls were comparable (males 87.5% and 82.5%; mean age 46.7±9.0 years and 42.0±9.8 years, respectively). Sustained virological response was achieved in 83.3% in the sofosbuvir group and in 47.6% of controls (P=0.003). Fatigue (P=0.007), flu-like (P=0.015), gastrointestinal (P<0.001), dermatologic (P<0.001) and psychiatric symptoms (P=0.022) were more common in the control group.
Conclusions: In our real-life cohort, sofosbuvir-based triple therapy confirmed its high efficacy and safety for chronic genotype 4 hepatitis C.
(Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: